October 17, 2025

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

Scrip Code: 543349

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot No. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

NSE Symbol: ACUTAAS

Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release discussing the financial results of second quarter and half year ended as on September 30, 2025.

This Press Release will be available on the website of the Company **www.acutaas.com**.

Kindly take the same on record.

Yours faithfully,
For, ACUTAAS CHEMICALS LIMITED

EKTA KUMARI SRIVASTAVA
Digitally signed by EKTA KUMARI SRIVASTAVA
Date: 2025.10.17 12:22:44 +05'30'

ACUTAAS CHEMICALS LIMITED

Ekta Kumari Srivastava
Company Secretary & Compliance Officer

Encl: Press Release

PRESS RELEASE
For Immediate dissemination

Acutaas Chemicals Limited reports Q2 FY26 Results

Q2 FY26 Revenue from Operation at ₹ 3,062mn, up 24.1% YoY

Q2 FY26 EBITDA Margin Expanded by 1130 bps YoY to 31.1%

Surat, October 17, 2025: Acutaas Chemicals Limited (BSE: 543349, NSE: ACUTAAS), a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, today announced financial results for the quarter and half year ended September 30, 2025.

Consolidated Financial Results – Q2 & H1FY26:

Particulars (Rs. Mn)	Q2FY26	Q2FY25	YoY-Q	Q1FY26	QoQ	H1FY26	H1FY25	YoY
Revenue from Operations	3,062	2,467	*24.1%*	2,072	*47.8%*	5,134	4,234	*21.3%*
Gross Profit	1,707	1,072	*59.3%*	1,103	*54.7%*	2,811	1,815	*54.9%*
Gross Margin	*55.8%*	*43.4%*		*53.2%*		*54.7%*	*42.9%*	
EBITDA	953	489	*94.8%*	509	*87.2%*	1,462	784	*86.4%*
EBITDA Margin	*31.1%*	*19.8%*		*24.6%*		*28.5%*	*18.5%*	
PAT	719	376	*91.3%*	440	*63.3%*	1,159	523	*121.7%*
PAT Margin	*23.5%*	*15.2%*		*21.2%*		*22.6%*	*12.3%*	

Commenting on results, Mr. Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals Limited, said: *"Our focus has always been on building a long-term, sustainable business rather than chasing short-term opportunities. This disciplined approach is now yielding tangible results as we strengthen global partnerships and expand into new growth verticals such as Battery Chemicals and Semiconductors.*

In Q2 FY26, our revenue grew by 24.1% year-on-year to ₹3,062 million, driven by strong performance in Advanced Pharmaceutical Intermediates and stable contributions from Specialty Chemicals.

We remain confident of delivering around 25% revenue growth for the full year, backed by a resilient business foundation and clear strategic direction"

Key Results & Business Highlights (Q2FY26 Consolidated):

- ✓ **Revenue from operations** for Q2FY26 grew by **24.1% YoY to Rs. 3,062 mn**
- ✓ The **gross margin** for the quarter improved to **55.8%** up 1,232 bps YoY
- ✓ **EBITDA** for the quarter came at **Rs. 953 mn** up 94.8% YoY
- ✓ **EBITDA margin** for the quarter was at **31.1%** as compared to 19.8% in Q2FY25
- ✓ **PAT** for the quarter was **Rs. 719 mn** up 91.3% as compared to PAT of Rs. 376 mn in Q2FY25
- ✓ The **PAT margin** for the quarter was at **23.5%** up 824 bps YoY
- ✓ Export for the quarter at **76%**; domestic business at **24%**

ABOUT ACUTAAS CHEMICALS LIMITED:

Acutaas Chemicals Limited is a speciality chemicals manufacturer serving a wide range of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Our core strength lies in the research-driven development and manufacturing of advanced pharmaceutical intermediates used in both regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs).

We are also expanding our portfolio to include high-value speciality chemicals for emerging technologies such as battery materials, semiconductor, and next-generation electronic applications. In addition, our offerings include parabens and their formulations, methyl salicylate, and niche key starting materials (KSMs) used in cosmetics and other industrial segments.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Acutaas Chemicals has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Acutaas Chemicals Limited	**Registered Office**
Ekta Srivastava, Company Secretary & Compliance Officer cs@acutaas.com **Senior Manager – Investor Relations** Mr. Rahul Thakur Rahul.thakur@acutaas.com	Plot no. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat- 394230 CIN: L24100GJ2007PLC051093 ISIN: INE00FF01025 NSE Code: ACUTAAS BSE CODE: 543349 Website: www.acutaas.com